ACEPROMAZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H22N2OS
Molecular Weight	326.456
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCCN1C2=C(SC3=C1C=C(C=C3)C(C)=O)C=CC=C2

InChI

InChIKey=NOSIYYJFMPDDSA-UHFFFAOYSA-N

InChI=1S/C19H22N2OS/c1-14(22)15-9-10-19-17(13-15)21(12-6-11-20(2)3)16-7-4-5-8-18(16)23-19/h4-5,7-10,13H,6,11-12H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C19H22N2OS
Molecular Weight	326.456
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/vet/acepromazine-maleate-injection.html | https://www.petmd.com/pet-medication/acepromazine

Acepromazine a potent neuroleptic agent with a low order of toxicity, is of particular value in the tranquilization of dogs, cats and horses. Its rapid action and lack of hypnotic effect are added advantages. Acepromazine is a commonly used tranquilizer/sedative in dogs, cats, horses, and other animals. Veterinarians typically prescribe acepromazine to quiet agitated animals or use it as a part of an anesthetic protocol. It is important to note that when used alone, acepromazine is not an effective pain reliever and does little if anything to relieve a pet’s anxiety or fear. Acepromazine can also be used to treat motion sickness and nausea associated with car or plane rides. The mechanism by which acepromazine decreases a pet’s alertness is not fully understood. It is thought to block dopamine receptors in the brain or inhibit the activity of dopamine in other ways.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine receptor 60 Target ID: CHEMBL2096905 Sources: https://www.petmd.com/pet-medication/acepromazine \| https://www.drugbank.ca/drugs/DB01614	Antagonist 2778
neurological system process 6 Target ID: GO:0050877 Sources: https://www.drugs.com/vet/acepromazine-maleate-injection.html \| https://www.petmd.com/pet-medication/acepromazine	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Agitation (veterinary) 3 Sources: https://www.drugs.com/vet/acepromazine-maleate-injection.html https://www.petmd.com/pet-medication/acepromazine	Primary		Approved 8429	ACEPROMAZINE MALEATE Approved Use Actions: Acepromazine maleate has a depressant effect on the central nervous system and therefore, causes sedation, muscular relaxation and a reduction in spontaneous activity. It acts rapidly, exerting a prompt and pronounced calming effect. Indications: Dogs and Cats: Acepromazine Maleate Injection can be used as an aid in controlling intractable animals during examination, treatment, grooming, x-ray and minor surgical procedures; to alleviate itching as a result of skin irritation; as an antiemetic to control vomiting associated with motion sickness. Acepromazine Maleate Injection is particularly useful as a preanesthetic agent (1) to enhance and prolong the effects of barbiturates, thus reducing the requirements for general anesthesia; (2) as an adjunct to surgery under local anesthesia. Horses: Acepromazine Maleate Injection can be used as an aid in controlling fractious animals during examination, treatment, loading and transportation. Particularly useful when used in conjunction with local anesthesia for firing, castration, neurectomy, removal of skin tumors, ocular surgery and applying casts.
Schizophrenia 298 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13536530	Primary		Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Application of pulsed Doppler ultrasound for the evaluation of small intestinal motility in dogs.	2001 Apr	14614298
Prospective survey of tick paralysis in dogs.	2001 Jun	11491220
Normal spatial memory following postseizure treatment with ketamine: selective damage attenuates memory deficits in brain-damaged rodents.	2001 Mar	11328682
Optimization of intraperitoneal injection anesthesia in mice: drugs, dosages, adverse effects, and anesthesia depth.	2001 Oct	11924805
[Sent home while still sleeping].	2001 Oct 1	11677793
Effects of medetomidine and buprenorphine administered for sedation in dogs.	2001 Sep	11570387
Intraocular pressure and tear production in five herbivorous wildlife species.	2002 Aug 31	12233828
The brain matrix and multifocal brain damage following a single injection of ketamine in young adult rats: conspicuous changes in old age.	2002 Dec	12509193
[Priapism in the stallion].	2002 Dec 15	12516385
Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA.	2002 Feb	11880033
The effects of xylazine, detomidine, acepromazine and butorphanol on equine solid phase gastric emptying rate.	2002 Jul	12358052
Evaluation of the perioperative stress response in dogs administered medetomidine or acepromazine as part of the preanesthetic medication.	2002 Jul	12118677
Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening.	2002 Jun	12079782
Effects of preoperative administration of ketoprofen on anesthetic requirements and signs of postoperative pain in dogs undergoing elective ovariohysterectomy.	2002 Nov 1	12418691
Reduced resident time and pharmacodynamic effects of acepromazine after subclinical multiple dosage in exercised thoroughbreds.	2002 Oct	12423229
A comparison of the analgesic effects of butorphanol with those of meloxicam after elective ovariohysterectomy in dogs.	2003 Jul	12892286
Hypotensive effect of push-pull gravitational stress occurs after autonomic blockade.	2003 Jul	12794095
Progressive changes in ophthalmic blood velocities in Beagles with primary open angle glaucoma.	2003 Mar	12641848
Changes in intraocular pressure and pupil size following intramuscular administration of hydromorphone hydrochloride and acepromazine in clinically normal dogs.	2003 Mar	12641847
Effects of acepromazine on renal function in anesthetized dogs.	2003 May	12755300
Temporal changes in ventricular function assessed echocardiographically in conscious and anesthetized mice.	2003 Nov	14608286
A comparison of preoperative tramadol and morphine for the control of early postoperative pain in canine ovariohysterectomy.	2003 Oct	12925179
Comparison of preoperative carprofen and postoperative butorphanol as postsurgical analgesics in cats undergoing ovariohysterectomy.	2004 Jul	15268687
Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically.	2004 Jul	15235065
NF-kappaB p50 facilitates neutrophil accumulation during LPS-induced pulmonary inflammation.	2004 Jun 9	15189567
Sonographic features of drug-induced splenic congestion.	2004 May-Jun	15200260
Neuroleptanalgesia in wild Asian elephants (Elephas maximus maximus).	2004 Oct	15509293
Intentional overdose of Large Animal Immobilon.	2004 Oct	15359207
Effects of ovariohysterectomy on canine blood neutrophil respiratory burst: a chemiluminescence study.	2004 Sep-Oct	15362995
Therapeutic effects of Holmium-166 chitosan complex in rat brain tumor model.	2005 Feb 28	15744805
Laparoscopic nonanatomic hepatic resection employing the LigaSure device.	2005 Jan-Mar	15791967
Muscle metabolic changes associated with long-term inhalation anaesthesia in the horse analysed by muscle biopsy and microdialysis techniques.	2005 Mar	15737180
Gamma scintigraphic evaluation of a miniaturized AERx pulmonary delivery system for aerosol delivery to anesthetized animals using a positive pressure ventilation system.	2005 Spring	15741772

Patents

Sample Use Guides

In Vivo Use Guide

Acepromazine Maleate Injection may be given intravenously, intramuscularly or subcutaneously. The following schedule may be used as a guide to IV, IM or SC injections: Dogs: 0.25-0.5 mg/lb of body weight. Cats: 0.5-1 mg/lb of body weight. Horses: 2-4 mg/100 lb of body weight. 0.25 - 3 mg per kg body weight by oral administration.

Route of Administration: Other

In Vitro Use Guide

The crude extract of Chlamydia pneumoniae induced the differentiation of monocytes into macrophages in 45 ± 5% of the cells. Acepromazine significantly reduced the mean percentage of differentiated cells: with 10−5 M ACP, 18 ± % (p < 0.005) of the cells differentiated into macrophages and with 10−4 M the mean percentage of differentiated cells was equivalent to the control values: 5 ± 1% (p < 0.001). Viability of the differentiated and nondifferentiated THP-1 was = 98%.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:15:27 GMT 2023` Edited by `admin` on `Fri Dec 15 16:15:27 GMT 2023`
Record UNII	54EJ303F0R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACEPROMAZINE

Official Name

English

ATRAVET

Brand Name

English

CONCENTRAT VO34

Brand Name

English

ETHANONE, 1-(10-(3-(DIMETHYLAMINO)PROPYL)-10H-PHENOTHIAZIN-2-YL)-

Systematic Name

English

ACEPROMAZINE [MI]

Common Name

English

acepromazine [INN]

Common Name

English

ACEPROMAZINE [MART.]

Common Name

English

ACEZINE 2

Brand Name

English

ACETYLPROMAZINE

Common Name

English

10-(3-(DIMETHYLAMINO)PROPYL)PHENOTHIAZIN-2-YL METHYL KETONE

Systematic Name

English

ACP

Common Name

English

ACE

Common Name

English

Acepromazine [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN05AA04